Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright

Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $12.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 31.43% from the company’s previous close.

Several other research firms have also recently issued reports on SAGE. Wall Street Zen cut Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 7th. Bank of America began coverage on shares of Sage Therapeutics in a report on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 price target on the stock. Canaccord Genuity Group upped their price objective on shares of Sage Therapeutics from $8.00 to $8.50 and gave the stock a “hold” rating in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research report on Monday. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.93.

Sage Therapeutics Trading Up 0.1%

Sage Therapeutics stock opened at $9.13 on Tuesday. The firm has a market cap of $571.72 million, a P/E ratio of -1.57 and a beta of 0.18. Sage Therapeutics has a 1-year low of $4.62 and a 1-year high of $13.47. The firm has a 50-day moving average of $7.11 and a 200-day moving average of $6.93.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 747.63% and a negative return on equity of 68.99%. The business had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. During the same period in the previous year, the company earned ($1.80) EPS. The company’s revenue for the quarter was up 78.0% on a year-over-year basis. Research analysts forecast that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. US Bancorp DE increased its stake in Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 2,268 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Sage Therapeutics by 21.6% during the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 2,446 shares during the last quarter. Picton Mahoney Asset Management increased its position in shares of Sage Therapeutics by 126.0% during the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 3,581 shares in the last quarter. AlphaQuest LLC purchased a new position in Sage Therapeutics in the 1st quarter worth approximately $32,000. Finally, ProShare Advisors LLC lifted its position in Sage Therapeutics by 31.2% in the 4th quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company’s stock valued at $99,000 after acquiring an additional 4,350 shares in the last quarter. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.